drugset
drugset / Trial / NCT05019950

Safety Tolerability and Pharmacokinetics of Oral NIM-1324 in Healthy Adult Male and Female Volunteers

NCT05019950 ↗

Phase 1 Completed 56 enrolled NImmune Biopharma
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, ascending dose, multi-cohort study. The primary objective of this study is to assess the safety and tolerability of single and 7-day repeat oral doses NIM-1324 in healthy adult volunteers.

Timeline

Start
2021-10-28
Primary completion
2022-04-28
Completion
2022-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject NIM-1324 Unknown — Oral

Indications

No indication recorded.